Astellas Pharma Inc ▲ Sign in to save

• ▲ Benoît Baron

  Johnson & Johnson (United States) · Janssen (Netherlands) Medicine
  3.2k

  citations

  19

  h-index

  3

  Aachen papers
• ▲ Stefan Holmström

  Astellas Pharma (Netherlands) Economics, Econometrics and Finance
  831

  citations

  15

  h-index

  3

  Aachen papers
• ▲ Delphine Ammar

  Astellas Pharma (Netherlands) Immunology and Microbiology
  52

  citations

  3

  h-index

  5

  Aachen papers
• ▲ Mary Mantock

  Astellas Pharma (Netherlands) Medicine
  37

  citations

  1

  h-index

  1

  Aachen papers

4 results

• Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

  2022 Journal for ImmunoTherapy of Cancer article Medicine CAR-T cell therapy research Open access cited by 6 patents

  37

  citations
• Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

  2021 International Journal of Urology article Medicine Prostate Cancer Treatment and Research Open access

  22

  citations
• A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE

  2021 International Journal of Cancer article Medicine Prostate Cancer Treatment and Research Open access

  18

  citations
• Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan

  2021 Japanese Journal of Clinical Oncology article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access

  10

  citations

4 results